Patents by Inventor Joshua McElwee

Joshua McElwee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GENETIC MARKERS ASSOCIATED WITH RESPONSE TO CRTH2 RECEPTOR ANTAGONISTS
    Publication number: 20210348235
    Abstract: The present invention provides genetic markers on human chromosome 1 that are associated with a beneficial response to CRTH2 receptor antagonists. These CRTH2 receptor antagonist response markers are useful, inter alia, to identify patients who are most likely to benefit from treatment with CRTH2 receptor antagonist compositions and drug products, in methods of treating patients having a disease susceptible to treatment with a CRTH2 receptor antagonist, and in methods for selecting the most appropriate therapy for such patients.
    Type: Application
    Filed: July 16, 2021
    Publication date: November 11, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Gregory J. Opiteck, Peggy H. Wong, Joshua McElwee, Devan V. Mehrotra, Steven Greenberg, Zifang Guo
  • Genetic markers associated with response to CRTH2 receptor antagonists
    Patent number: 11091806
    Abstract: The present invention provides genetic markers on human chromosome 1 that are associated with a beneficial response to CRTH2 receptor antagonists. These CRTH2 receptor antagonist response markers are useful, inter alia, to identify patients who are most likely to benefit from treatment with CRTH2 receptor antagonist compositions and drug products, in methods of treating patients having a disease susceptible to treatment with a CRTH2 receptor antagonist, and in methods for selecting the most appropriate therapy for such patients.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: August 17, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Gregory J. Opiteck, Peggy H. Wong, Joshua McElwee, Devan V. Mehrotra, Steven Greenberg, Zifang Guo
  • GENETIC MARKERS ASSOCIATED WITH RESPONSE TO CRTH2 RECEPTOR ANTAGONISTS
    Publication number: 20180237856
    Abstract: The present invention provides genetic markers on human chromosome 1 that are associated with a beneficial response to CRTH2 receptor antagonists. These CRTH2 receptor antagonist response markers are useful, inter alia, to identify patients who are most likely to benefit from treatment with CRTH2 receptor antagonist compositions and drug products, in methods of treating patients having a disease susceptible to treatment with a CRTH2 receptor antagonist, and in methods for selecting the most appropriate therapy for such patients.
    Type: Application
    Filed: July 21, 2016
    Publication date: August 23, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Gregory J. Opiteck, Peggy H. Wong, Joshua McElwee, Devan V. Mehrotra, Steven Greenberg, Zifang Guo
  • BIOMARKERS FOR PSORIASIS TREATMENT RESPONSE
    Publication number: 20150322519
    Abstract: Single nucleotide polymorphisms (SNPs) are provided that correlate with responsiveness of psoriasis patients to treatment with a therapeutic antibody that specifically binds to the p19 subunit of IL-23. The SNPs are used as biomarkers to prospectively selecting psoriasis patients likely to benefit from treatment with antagonists of IL-23, such as an antibody that specifically binds to the p19 subunit of IL-23.
    Type: Application
    Filed: December 19, 2013
    Publication date: November 12, 2015
    Inventors: Joshua McElwee, Robin Mogg, Devan Mehrotra